Home > Healthcare > Pharmaceuticals > Finished Drug Form > Biobetters Market

Biobetters Market Share

Report ID: GMI11126
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Biobetters Market Share

The biobetters industry is marked by intense competition, with both large global companies and smaller to medium-sized firms striving for market dominance. A crucial aspect of market strategy is the continuous introduction of innovative products that employ diverse technologies. Leading industry players drive innovation through substantial investments in research and development. Additionally, strategic partnerships, acquisitions, and mergers are pivotal in bolstering market positions and expanding international reach.

Biobetters Market Companies

Some of the eminent market participants operating in the biobetters industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Biogen Inc.
Bristol-Myers Squibb Company
Celltrion Inc.
Eli Lilly And Company
F. Hoffmann-La Roche Ltd.
GSK plc
Kiniksa Pharmaceuticals, Ltd.
Merck & Co., Inc.
Novo Nordisk A/S
Regeneron Pharmaceuticals, Inc.
Sanofi
Teva Pharmaceutical Industries Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Biobetters market size was valued at USD 52.8 billion in 2023 and is estimated to grow at 8.3% CAGR from 2024 to 2032 driven by the increasing prevalence of chronic diseases.

The monoclonal antibodies segment in the market is forecasted to reach USD 38.5 billion by 2032 as they offer high specificity and efficacy by targeting precise antigens involved in these diseases.

The U.S. biobetters market is projected to reach USD 44.1 billion by 2032 owing to the FDA’s initiatives, such as expedited review processes and incentives for novel therapies.

AbbVie Inc., Amgen Inc., AstraZeneca PLC,. Biogen Inc., Bristol-Myers Squibb Company, Celltrion Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., GSK plc, Kiniksa Pharmaceuticals, Ltd., Merck & Co., Inc., and Novo Nordisk A/S among others.